CTAD 2023: Grifols/Araclon Ponder Next Steps For ABvac40 After Phase II Readout

Ongoing Mid-Stage Data Analysis Will Inform Trial Plans

 
• By Mandy Jackson

The Phase II trial was not powered to show statistical significance on cognitive efficacy, but early Alzheimer’s patients treated with Araclon/Grifols’ anti-Aβ40 vaccine had slower decline by some measures.

Abstract blue brain. Brain anatomy.
Brain atrophy was not as pronounced in ABvac40-treated patients • Source: Shutterstock

More from Clinical Trials

More from R&D